BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, announced today that the results of ARC002, an open-label Phase 2 continuation trial of Aimmune’s lead investigational product, AR101 for the treatment of peanut allergy, will be presented at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Los Angeles.
